NCT01531322View on ClinicalTrials.gov

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Pneumococcal Infection
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Trial Locations (2)

210009

Pfizer Investigational Site, Nanjing

223300

Pfizer Investigational Site, Huaian

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01531322 - A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter